Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Reata Pharmaceuticals revenue
Reata Pharmaceuticals's revenue is $2.2 million.
What is Reata Pharmaceuticals's revenue?
- Reata Pharmaceuticals's revenue growth from 2015 to 2022 is -95.6%.
- Reata Pharmaceuticals has 346 employees, and the revenue per employee ratio is $6,404.
- Reata Pharmaceuticals's peak quarterly revenue was $32.4M in 2018(q1).
- Reata Pharmaceuticals peak revenue was $53.6M in 2018.
- Reata Pharmaceuticals annual revenue for 2021 was 11.5M, 27.4% growth from 2020.
- Reata Pharmaceuticals annual revenue for 2022 was 2.2M, -80.71% growth from 2021.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Reata Pharmaceuticals historical revenue
Reata Pharmaceuticals's peak revenue was $53.6M in 2018. The peak quarterly revenue was $32.4M in 2018(q1).
Reata Pharmaceuticals's revenue increased from $50.3m in 2015 to $2.2M currently. That's a -95.6% change in annual revenue.
Reata Pharmaceuticals annual revenue
Reata Pharmaceuticals annual revenue over time
| Fiscal year / year | Reata Pharmaceuticals revenue |
|---|---|
| 2015 | $50.3M |
| 2016 | $49.9M |
| 2017 | $48.1M |
| 2018 | $53.6M |
| 2019 | $26.5M |
| 2020 | $9.0M |
| 2021 | $11.5M |
| 2022 | $2.2M |
How accurately did Reata Pharmaceuticals' revenue projections match actual performance?
Reata Pharmaceuticals annual growth
Reata Pharmaceuticals saw the greatest revenue growth in 2021, when revenue increased by 27.4%.
Reata Pharmaceuticals had the lowest revenue growth in 2022, when revenue changed by -80.71%.
Reata Pharmaceuticals annual growth rate over time
| Year | Reata Pharmaceuticals growth |
|---|---|
| 2016 | -1%↓ |
| 2017 | -4%↓ |
| 2018 | 12%↑ |
| 2019 | -51%↓ |
| 2020 | -66%↓ |
| 2021 | 27%↑ |
| 2022 | -81%↓ |
Reata Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Reata Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2016 | - | $12.4M | $12.6M | $12.5M |
| 2017 | $12.7M | $12.8M | $12.6M | $10.0M |
| 2018 | $32.4M | $7.6M | $5.2M | $8.5M |
| 2019 | $7.8M | $7.8M | $8.2M | $2.7M |
| 2020 | $1.4M | $3.1M | $1.4M | $3.2M |
| 2021 | $944,000 | $2.2M | $7.4M | $933,000 |
| 2022 | $914,000 | $762,000 | $540,000 | - |
| 2023 | $195,000 | $22.7M | - | - |
Reata Pharmaceuticals jobs nearby
Do you work at Reata Pharmaceuticals?
Is Reata Pharmaceuticals transparent about its revenue structure?
Reata Pharmaceuticals financial information
| CEO | J. Warren Huff |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 346 |
| Date Founded | 2002 |
| Headquarters | Irving, Texas |
| Number of Locations | 2 |
| Revenue | $2.2M |
| Net Income | -$311,901,000 |
| Tax Rate | 0.0% |
| Total Assets | $514,491,000 |
| Ticker | RETA |
Reata Pharmaceuticals jobs you might like
Reata Pharmaceuticals financing
Reata Pharmaceuticals received early financing of $1.6M on 2002-09-27.
| Series | Round size | Date |
|---|---|---|
| Series A | $1.6M | 09/2002 |
| Series B | $3.6M | 09/2003 |
| Series C | $12M | 11/2004 |
| Series D | $7M | 06/2006 |
| Series E | $25M | 07/2007 |
| Series F | $30.7M | 12/2008 |
| Series Unknown | $17.0M | 09/2009 |
| Series Unknown | $2.0M | 02/2010 |
| Series Unknown | $78M | 07/2010 |
| Series Unknown | $300M | 07/2011 |
| Post Ipo Debt | $35M | 04/2017 |
| Post Ipo Equity | $505M | 11/2019 |
| Post Ipo Equity | $350M | 06/2020 |
Reata Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Startech Early Ventures | Series A |
| Ojai Goliad | Series B |
| Startech Early Ventures | Series C |
| Cardinal Investment Co | Series C |
| University of Texas At Austin | Series C |
| Ojai Goliad | Series C |
| Novo Holdings A | Series D |
| Startech Early Ventures | Series D |
| Cardinal Investment Co | Series D |
| Ojai Goliad | Series D |
| Novo Holdings A | Series E |
| CPMG | Series E |
| Novo Holdings A | Series Unknown |
| CPMG | Series Unknown |
| Oxford Finance LLC | Post Ipo Debt |
| Silicon Valley Bank | Post Ipo Debt |
| Blackstone Life Sciences | Post Ipo Equity |
Reata Pharmaceuticals competitors
Reata Pharmaceuticals's top competitor, Exelixis, earned an annual revenue of $2.2B.
Reata Pharmaceuticals's smallest competitor is Intralytix with revenue of $3.8M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Intercept Pharmaceuticals | - | $285.7M | 437 | - |
| ImmunoGen | - | $108.8M | 75 | - |
| Exelixis | - | $2.2B | 484 | - |
| GlobeImmune | - | $6.5M | 22 | - |
| Allos Therapeutics | - | $76.0M | 175 | - |
| Cortex Pharmaceuticals | - | - | 9 | - |
| Intralytix | - | $3.8M | 36 | - |
| Nanotherapeutics, Inc. | - | - | - | - |
| Paddock Laboratories | - | $100.5M | 51 | - |
| Mylan | - | $11.5B | 35,000 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Reata Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Reata Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Reata Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Reata Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Reata Pharmaceuticals. The data presented on this page does not represent the view of Reata Pharmaceuticals and its employees or that of Zippia.
Reata Pharmaceuticals may also be known as or be related to REATA PHARMACEUTICALS INC, Reata Pharmaceuticals, Reata Pharmaceuticals Inc and Reata Pharmaceuticals, Inc.